Orion OYJ Debt/Equity Ratio 2017-2025 | ORINY

Orion OYJ debt/equity ratio for the quarter ending March 31, 2025 was 0.27.

  • Orion OYJ average debt/equity ratio for 2024 was 0.27, a 17.39% decline from 2023.
  • Orion OYJ average debt/equity ratio for 2023 was 0.23, a 9.52% increase from 2022.
  • Orion OYJ average debt/equity ratio for 2022 was 0.21, a 40% increase from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Orion OYJ Debt/Equity Ratio 2017-2025 | ORINY

  • Orion OYJ average debt/equity ratio for 2024 was 0.27, a 17.39% decline from 2023.
  • Orion OYJ average debt/equity ratio for 2023 was 0.23, a 9.52% increase from 2022.
  • Orion OYJ average debt/equity ratio for 2022 was 0.21, a 40% increase from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$80.2B
Zoetis (ZTS)$68.3B
Daiichi Sankyo, - (DSNKY)$47.1B
Takeda Pharmaceutical (TAK)$46.9B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$26.4B
Summit Therapeutics (SMMT)$20.8B
Merck (MKKGY)$17.3B
Shionogi (SGIOY)$14.5B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13.2B
IPSEN (IPSEY)$10.9B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.3B
Madrigal Pharmaceuticals (MDGL)$6.8B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
Procaps Group, S.A (PROCF)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B